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Abstract 
The authors report the first catheter ablation of Brugada syndrome in the literature 
using the Rhythmia-mapping system. Learning points include: 1. Low voltage areas can 
be documented while mapping in some these individuals, and suggesting that Brugada 
syndrome may not be a pure ion channel disorder. 2. Typical long-fractionated 
potentials can also be identified in the endocardium, supporting the need of mapping the 
endocardium in all Brugada patients requiring an ablation. 3. Disappearance of the 
typical coved-pattern following ablation does not necessarily predict cure as the case we 
presented still experienced ventricular fibrillation relapse a few months later. 






Os autores descrevem a primeira ablação de Síndrome de Brugada usando o sistema de 
mapeamento Rhythmia. Pontos de aprendizagem incluem: 1. É possível observar fibrose 
ao mapear alguns destes indivíduos, sugerindo que a Síndrome de Brugada poderá não 
ser uma canalopatia pura. 2. Os potenciais fraccionados de longa duração também 
podem ser identificados no endocárdio, reforçando a necessidade de mapeamento 
também do endocárdio em todos os doentes com Brugada com indicação para ablação. 
3. Desaparecimento do padrão típico “coved” não prevê necessariamente a cura uma vez 
que no caso apresentado uma recidiva de fibrilhação ventricular foi observada alguns 
meses mais tarde. 
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A 39 year-old male with Brugada syndrome (BS) and recurrent arrhythmia storms 
(nearly once a month) due to ventricular fibrillation (VF) resistant to maximum 
tolerated dose of quinidine was referred to catheter ablation in our Center. His heart 
was structurally normal, with normal left and right ventricular systolic function, no 
chamber dilation or ventricular wall motion abnormalities on recent echocardiogram 
assessment, and MRI performed years before. He had been implanted with an 
implantable cardioverter defibrillator following an out of hospital ventricular fibrillation 
episode. 
The patient presented with spontaneous type-1 pattern at the start of the procedure 
(Panel 1A), and both endocardial and epicardial access was obtained. The RhythmiaTM 
mapping system (Boston Scientific©, Massachusetts, USA) was used, and after mapping 
with the Intellamap OrionTM catheter (Boston Scientific©, Massachusetts, USA) 
fractionated potentials were targeted using the IntellanavTM Open-Irrigated catheter 
(Biosense Webster©, California, USA) (Panel 2). Some fractionated potentials were 
found in the right ventricular outflow tract (RVOT) endocardium (Panel 3), but longer 
potentials, measuring > 200 to 300ms, were observed mostly in the epicardial layer 
(Panel 4) (potential duration was measured from start to end of local EGM using the 
method described by Pappone et al. [1]). Interestingly, areas of scar were also detected 
in the right ventricular outflow tract endocardium and epicardium (Panels 2 and 3). 
Following ablation in the area (40W 30s per lesion until eradication of the long duration 
potentials), the coved type-1 pattern disappeared. After 9 months of follow-up, and no 
relapse of the coved-type 1 pattern (Panel 1B), the patient had a single episode of VF in 
the second month, and is now free from arrhythmia drugs. 
This first case BS ablation using the RhythmiaTM mapping system illustrates three 
important aspects: First, fibrosis can also present in some individuals with BS who do 
not meet criteria for arrhythmogenic right ventricular dysplasia. This fact had already 
been suggested by Coronel and colleagues [2]. Whether fibrosis results from a more 
aggressive channelopathy form where channel dysfunction leads to tissue changes, 
additional mutations or polymorphisms in different genes, or modulators leading to 
fibrosis, or fortuitous occurrence of localized myocarditis, remains to be explained. In 
this case no mutation or polymorphism could be identified, and therefore we cannot 
provide data to support the abovementioned hypothesis. However, a recent publication 
suggests that BS patients with SCN5A may exhibit more conduction abnormalities on 
ECG and have higher risk for cardiac events (Ref Yamagata et al). Nademanee and 
colleagues have shown increased collagen, fibrosis and reduced gap junction signalling 
protein Cx43 expression in the RVOT are present in BS patients [Nademanee et al 2015]. 
These data support the plausibility of BS reflecting a generalized disease of myocardial 
architecture, and the baseline properties of the RVOT which predispose it to fibrosis are 
likely to contribute to the condition and its arrhythmic risk. Presence of coexistent 
fibrosis may explain why up to 5% of patients BS may also develop monomorphic 
ventricular tachycardias [3]. Second, our findings of fractionated potentials in the 
endocardium (Panel 3) suggest there may still be a rational to chase ventricular ectopics 
originating from the area or ablating endocardial long-duration potentials [4]. In our 
case, as these potentials were only identified on retrospective analysis of the map and, 
therefore, not ablated, we cannot help but wonder if the preservation of this zone is the 
reason why the patient relapsed. A recent investigation using simultaneous non-invasive 
mapping of the endo and epicardium suggests that the both endo and epicardium 
appear to be involved in a substancial number of patients, and their interplay appears to 
play a role in the observed phenotype [Ref Documentation of abnormalities in 
endocardial and epicardial electrograms  Also, these are located in the low postero-
septal region of the RVOT, which does not correspond to the traditional area of 
epicardial involvement in BS.  Third, disappearance of the coved-pattern does not 
necessarily predict cure. In this case we hypothesize that several factors may have 
contributed: a) existence of an underlying fibrotic substrate (which may have been 
aggravated with ablation); b) reduced transmyocardial repolarization gradient which 
was not enough to result in a coved type-1 pattern, but in the presence of an 
appropriately timed ventricular ectopic was still enough to degenerate into VF. Finally, 
much remains yet to be learned about BS, and the growing number of catheter ablations 
for this disease will surely help expand our knowledge. 
Using RhythmiaTM mapping system and taking advantage of its high-density mapping 
capabilities appears to be advantageous in this setting as very precise mapping, with no 
limit in the number of collected points, and identification of the culprit potentials is 
likely to have an impact on procedural success and prognosis of these patients. 
Furthermore, if the future of mapping in this condition is to follow the approach used by 
Pappone and colleagues, where repeated maps are performed following ablation and 
repeated ajmaline infusion, the ultra-rapid mapping potential of RhythmiaTM will make it 
a likely candidate for usage in this setting. 
The definition that can be obtained with high-density mapping contrasts with the 
resolution of point-by-point mapping using other mapping systems. For example, our 
epicardial map was composed of 50,472 electrograms, which is > 100 times more 
detailed to what has been described in a previous case report where only 304 points 
were collected [Ref Cortez Dias et al. 2012 Rev Port Cardiol].  
In our case, we did not perform post-ablation ajmaline testing or programmed 
ventricular stimulation. The controversy regarding programmed ventricular stimulation 
has lasted for decades in the setting of risk assessment. Even though it has been used by 
authors [Ref Pappone e Cortez Dias] its role as a predictor of success of catheter ablation 








Figure. Panel 1 Pre-cordial leads (V1 to V3) showing presence of spontaneous type-1 
Brugada pattern at the start of the procedure, and its disappearance 9 months after; 
Panel 2 – Epicardial voltage map of the right ventricle using RhythmiaTM mapping 
system, AP view, with 0.5 and 1.5mV as voltage cut-off points showing wide areas of 
fibrosis in the RVOT and anterior wall of the right ventricle. Panel 3 – Endocardial 
voltage map of the right ventricle, PA view, showing an area of fibrosis in the postero-
septal aspect of the RVOT. A long (>120ms), complex, small amplitude and fractionated 
potential is highlighted. Panel 4 – Potential duration map of the epicardial aspect of the 
right ventricle, AP view, showing area of potentials lasting longer than 291ms (purple), 
corresponding to the ablated zone. Areas of potentials lasting less than 200ms are 
coloured in red. Highlighted is a very long and complex potential measuring 
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